Functional Concept
FDA Approves Axsome’s Symbravo for Rapid Migraine Relief
Symbravo, meloxicam, rizatriptan, FDA approval, acute migraine treatment, rapid-acting, Axsome Therapeutics
FDA Approves Axsome’s Symbravo for Acute Migraine Treatment, Overcoming 2022 Rejection
Symbravo, Axsome Therapeutics, FDA approval, acute migraine treatment, meloxicam, rizatriptan, MoSEIC technology
Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism
Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends
Merck Halts HYPERION Trial of Winrevair Early Due to Overwhelming Efficacy in PAH Treatment
Winrevair, sotatercept-csrk, pulmonary arterial hypertension (PAH), HYPERION trial, clinical equipoise, Merck, early trial termination
Cargo Therapeutics Discontinues Lead CAR-T Program Due to Poor Durability and Safety Concerns
CAR-T therapy, durability, safety, clinical trial discontinuation, large B-cell lymphoma, firi-cel, CARGO Therapeutics
Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer
Kailera Therapeutics, Jamie Coleman, Chief Commercial Officer, Obesity Treatment, Zepbound, Eli Lilly
Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures
Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis
Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring
Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.
Aurion Biotech Presses On with IPO Plans Amid Legal Dispute with Investor Alcon
Aurion Biotech, IPO, legal dispute, Alcon, cell therapy, biotech investment
Metsera Raises $275M in IPO to Advance GLP-1 Weight Loss Drug to Phase 3
Metsera, IPO, GLP-1 receptor agonist, MET-097i, obesity treatment, weight loss drug, clinical trials, biotech funding